Cited by 573Lung Cancer Treatments and MutationsLung Cancer Diagnosis and TreatmentLung Cancer Research Studies

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023

Open access

Kelly, Karen, Chansky, Kari, Gaspar, Laurie E., Albain, Kathy S., Jett, James, Ung, Yee C., Lau, Derick H.M., Crowley, John J., Gandara, David R.·2008·Journal of Clinical Oncology

DOI 10.1200/jco.2007.14.4824

Open this paper in CoChat — free account Open PDF

Abstract

PURPOSE: Early clinical studies with gefitinib showed promising efficacy and mild toxicity in patients with advanced non-small-cell lung cancer (NSCLC). Thus, gefitinib was an ideal agent to evaluate in a maintenance setting in stage III disease. PATIENTS AND METHODS: Untreated patients with stage III NSCLC, a performance score of 0 to 1, and adequate organ function were eligible. All patients received cisplatin 50 mg/m(2) on days 1 and 8 plus etoposide 50 mg/m(2) on days 1 to 5, every 28 days for two cycles with concurrent thoracic radiation (1.8- to 2-Gy fractions per day; total dose, 61 Gy) followed by three cycles of docetaxel 75 mg/m(2). Patients whose disease did not progress were randomly assigned to gefitinib 250 mg/d or placebo until disease progression, intolerable toxicity, or the end of 5 years. The planned sample size was 672 patients to confer power of 0.89 to detect a 33% increase over the expected median survival time of 21 months (one-sided P = .025, log-rank test). Random assignment was stratified by stage, histology, and measurable versus nonmeasurable disease. RESULTS: Enrollment began in July 2001. An unplanned interim analysis conducted in April 2005 rejected the alternative hypothesis of improved survival at the P = .0015 level for 243 randomly assigned patients. The study closed, and preliminary results were reported. Now, with a median follow-up time of 27 months, median survival time was 23 months for gefitinib (n = 118) and 35 months for placebo (n = 125; two-sided P = .013). The toxic death rate was 2% with gefitinib compared with 0% for placebo. CONCLUSION: In this unselected population, gefitinib did not improve survival. Decreased survival was a result of tumor progression and not gefitinib toxicity.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1200/jco.2007.14.4824

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419
Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer
Fukuoka, M., Yano, S., Giaccone, G., Tamura, T., Nakagawa, K., Douillard, J., Nishiwaki, Y., Vansteenkiste, J., Kudoh, S., Rischin, D., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.10.038 · Cited by 2,871
Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non–Small Cell Lung Cancer: A Randomized Trial
Kris, M. G., Natale, R. B., Herbst, R. S., Lynch, Jr., Prager, D., Belani, C. P., Schiller, J. H., Kelly, K., Spiridonidis, H., Sandler, A., et al. (2003) · JAMA · doi:10.1001/jama.290.16.2149 · Cited by 2,517
Self-citation
Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)
Thatcher, N., Chang, A., Parikh, P., Rodrigues Pereira, J., Ciuleanu, T., von Pawel, J., Thongprasert, S., Tan, E. H., Pemberton, K., Archer, V., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67625-8 · Cited by 2,079
Erlotinib in Lung Cancer — Molecular and Clinical Predictors of Outcome
Tsao, M., Sakurada, A., Cutz, J.-C., Zhu, C., Kamel‐Reid, S., Squire, J. A., Lorimer, I. A. J., Zhang, T., Liu, G., Daneshmand, M., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050736 · Cited by 1,815
Gefitinib in Combination With Gemcitabine and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 1
Giaccone, G., Herbst, R. S., Manegold, C., Scagliotti, G. V., Rosell, R., Miller, V. A., Natale, R. B., Schiller, J. H., von Pawel, J., Pluzanska, A., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.001 · Cited by 1,712
Gefitinib in Combination With Paclitaxel and Carboplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 2
Herbst, R. S., Giaccone, G., Schiller, J. H., Natale, R. B., Miller, V. A., Manegold, C., Scagliotti, G. V., Rosell, R., Oliff, I. A., Reeves, J. A., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.07.215 · Cited by 1,701
KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib
Pao, W. J., Wang, T. Y., Riely, G. J., Miller, V. A., Pan, Q., Ladanyi, M., Zakowski, M. F., Heelan, R. T., Kris, M. G., & VARMUS, H. E. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020017 · Cited by 1,517
TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer
Herbst, R. S., Prager, D., Hermann, R., Fehrenbacher, L., Johnson, B. E., Sandler, A., Kris, M. G., Tran, H. T., Klein, P., Li, X., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.840 · Cited by 1,490

Flagged first, then by citations

Show all 31 references

Sorted by citations

Items 101–200 of 573

A Phase II Study of Induction Chemotherapy Followed by Thoracic Radiotherapy and Erlotinib in Poor-Risk Stage III Non–Small-Cell Lung Cancer: Results of CALGB 30605 (Alliance)/RTOG 0972 (NRG)
Lilenbaum, R., Samuels, M. A., Wang, X., Kong, F., Janne, P. A., Masters, G. A., Katragadda, S., Hodgson, L. C., Bogart, J. A., Bradley, J. D., et al. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000347 · Cited by 55
Asian Thoracic Oncology Research Group Expert Consensus Statement on Optimal Management of Stage III NSCLC
Tan, W. L., Chua, K. L. M., Lin, C., Lee, V. H.-F., Tho, L. M., Chan, A. W. H., Ho, G. F., Reungwetwattana, T., Yang, J. C., Kim, D., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.10.022 · Cited by 55
SEOM clinical guidelines for the treatment of non-small cell lung cancer (NSCLC) 2015
García‐Campelo, R., Bernabé, R., Cobo, M., Corral, J., Coves, J., Dómine, M., Nadal, E., Rodríguez‐Abreu, D., Viñolas, N., & Massutí, B. (2015) · Clinical & Translational Oncology · doi:10.1007/s12094-015-1455-z · Cited by 55
Folliculitis Induced by EGFR Inhibitors, Preventive and Curative Efficacy of Tetracyclines in the Management and Incidence Rates According to the Type of EGFR Inhibitor Administered: A Systematic Literature Review
Bachet, J., Peuvrel, L., Bachmeyer, C., Reguiaï, Z., Gourraud, P., Bouché, O., Ychou, M., Bensadoun, R., Dréno, B., & André, T. (2012) · The Oncologist · doi:10.1634/theoncologist.2011-0365 · Cited by 53
Concurrent cetuximab and radiotherapy after docetaxel–cisplatin induction chemotherapy in stage III NSCLC: Satellite—A phase II study from the Swedish Lung Cancer Study Group
Hallqvist, A., Wagenius, G., Rylander, H., Brodin, O., Holmberg, E. C., Lödén, B., Ewers, S., Bergström, S. N., Wichardt-Johansson, G., Nilsson, K. L., et al. (2010) · Lung Cancer · doi:10.1016/j.lungcan.2010.05.011 · Cited by 53
Risk of oral and gastrointestinal mucosal injury among patients receiving selected targeted agents: a meta-analysis
Elting, L. S., Chang, Y.-C., Parelkar, P., Boers-Doets, C. B., Michelet, M., Hita, A. G., Rouleau, T., Cooksley, C. D., Halm, J. K., Vithala, M. V., et al. (2013) · Supportive Care in Cancer · doi:10.1007/s00520-013-1821-8 · Cited by 55
Synergistic Effect of Afatinib with Su11274 in Non-Small Cell Lung Cancer Cells Resistant to Gefitinib or Erlotinib
Chen, G., Noor, A., Kronenberger, P., Teugels, E., Umelo, I. A., & Grève, J. D. (2013) · PLoS ONE · doi:10.1371/journal.pone.0059708 · Cited by 51
Emerging role of gefitinib in the treatment of non-small-cell lung cancer (NSCLC)
Tiseo, M. (2010) · Drug Design Development and Therapy · doi:10.2147/dddt.s6594 · Cited by 51
A Pilot Trial of Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Docetaxel and the Combination of Bevacizumab (NSC-704865) in Patients With Inoperable Locally Advanced Stage III Non–Small-Cell Lung Cancer: SWOG S0533
Wozniak, A. J., Moon, J., Thomas, C. R., Kelly, K. L., Mack, P. C., Gaspar, L. E., Raben, D., FitzGerald, T. J., Pandya, K. J., & Gandara, D. R. (2015) · Clinical Lung Cancer · doi:10.1016/j.cllc.2014.12.014 · Cited by 51
Self-citation
The Role of Cancer-Testis Antigens as Predictive and Prognostic Markers in Non-Small Cell Lung Cancer
John, T., Starmans, M. H. W., Chen, Y., Russell, P. A., Barnett, S. A., White, S. C., Mitchell, P. L. R., Walkiewicz, M., Azad, A., Lambin, P., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0067876 · Cited by 50
Multidisciplinary team discussion results in survival benefit for patients with stage III non-small-cell lung cancer
Hung, H.-Y., Tseng, Y.-H., Chao, H., Chiu, C., Hsu, W., Hsu, H., Wu, Y., Chou, T., Chen, C.-K., Lan, K.-L., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0236503 · Cited by 53
Gefitinib in Combination With Irradiation With or Without Cisplatin in Patients With Inoperable Stage III Non–Small Cell Lung Cancer: A Phase I Trial
Rothschild, S. I., Bucher, S. E., Bernier, J., Aebersold, D. M., Zouhair, A., Ries, G., Lombrieser, N., Lippuner, T., Lütolf, U. M., Glanzmann, C., et al. (2010) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2010.01.048 · Cited by 48
Additional weekly Cetuximab to concurrent chemoradiotherapy in locally advanced non-small cell lung carcinoma: Efficacy and safety outcomes of a randomized, multi-center phase II study investigating
van den Heuvel, M. M., Uyterlinde, W., Vincent, A. D., de Jong, J., Aerts, J. G. J. V., Koppe, F. L. A., Knegjens, J., Codrington, H., Kunst, P. W. E., Dieleman, E. M. T., et al. (2013) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2013.10.009 · Cited by 47
Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort Study
Nassar, A. H., Kim, S. Y., Aredo, J. V., Feng, J., Shepherd, F. A., Xu, C., Kaldas, D., Gray, J. E., Dilling, T. J., Neal, J. W., et al. (2024) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2024.01.012 · Cited by 46
Long-Term Follow-Up of a Phase I/II Trial of Dose Escalating Three-Dimensional Conformal Thoracic Radiation Therapy with Induction and Concurrent Carboplatin and Paclitaxel in Unresectable Stage IIIA/B Non-small Cell Lung Cancer
Stinchcombe, T. E., Lee, C. B., Moore, D. T., Rivera, M. P., Halle, J. S., Limentani, S. A., Rosenman, J. G., & Socinski, M. A. (2008) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31818b1971 · Cited by 46
ACR Appropriateness Criteria Nonsurgical Treatment for Non–Small-Cell Lung Cancer: Poor Performance Status or Palliative Intent
Rosenzweig, K. E., Chang, J. Y., Chetty, I. J., Decker, R. H., Ginsburg, M. E., Kestin, L. L., Kong, F., Lally, B. E., Langer, C. J., Movsas, B., et al. (2013) · Journal of the American College of Radiology · doi:10.1016/j.jacr.2013.05.031 · Cited by 46
Early-Stage Non-Small Cell Lung Cancer: Surgery, Stereotactic Radiosurgery, and Individualized Adjuvant Therapy
Padda, S. K., Burt, B. M., Trakul, N., & Wakelee, H. A. (2013) · Seminars in Oncology · doi:10.1053/j.seminoncol.2013.12.011 · Cited by 46
Current and Future Treatment Options in the Management of Stage III NSCLC
Li, Y., Juergens, R. A., Finley, C., & Swaminath, A. (2023) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2023.08.011 · Cited by 46
Stage IIIA-N2 NSCLC: A review of its treatment approaches and future developments
van Meerbeeck, J. P., & Surmont, V. F. M. (2009) · Lung Cancer · doi:10.1016/j.lungcan.2009.02.007 · Cited by 45
EGFR Mutation Is Associated with Short Progression-Free Survival in Patients with Stage III Non-squamous Cell Lung Cancer Treated with Concurrent Chemoradiotherapy
Park, S. E., Noh, J. M., Kim, Y. J., Lee, H. S., Cho, J. H., Lim, S. W., Ahn, Y. C., Pyo, H., Choi, Y., Han, J., et al. (2018) · Cancer Research and Treatment · doi:10.4143/crt.2018.125 · Cited by 46
A Phase I Study of Gefitinib with Concurrent Dose-Escalated Weekly Docetaxel and Conformal Three-Dimensional Thoracic Radiation Followed by Consolidative Docetaxel and Maintenance Gefitinib for Patients with Stage III Non-small Cell Lung Cancer
Petty, W. J., Ayala, D. N., Hinson, W. H., Lovato, J. F., Capellari, J., Oaks, T. E., Miller, A. A., & Blackstock, A. W. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181c59a0e · Cited by 44
Management of Normal Tissue Toxicity Associated With Chemoradiation (Primary Skin, Esophagus, and Lung)
Yazbeck, V. Y., Villaruz, L., Haley, M., & Socinski, M. A. (2013) · The Cancer Journal · doi:10.1097/ppo.0b013e31829453fb · Cited by 44
Management of stage III non–small cell lung cancer
Tabchi, S., Kassouf, E., Rassy, E., Kourié, H. R., Martin, J., Campeau, M., Tehfe, M. A., & Blais, N. (2017) · Seminars in Oncology · doi:10.1053/j.seminoncol.2017.10.009 · Cited by 44
Real-world prospective analysis of treatment patterns in durvalumab maintenance after chemoradiotherapy in unresectable, locally advanced NSCLC patients
Taugner, J., Käsmann, L., Eze, C., Rühle, A., Tufman, A., Reinmuth, N., Duell, T., Belka, C., & Manapov, F. (2021) · Investigational New Drugs · doi:10.1007/s10637-021-01091-9 · Cited by 45
Molecular testing in stage I–III non-small cell lung cancer: Approaches and challenges
Aggarwal, C., Bubendorf, L., Cooper, W. A., Illei, P. B., Borralho, P., Ong, B., Tsao, M., Yatabe, Y., & Kerr, K. M. (2021) · Lung Cancer · doi:10.1016/j.lungcan.2021.09.003 · Cited by 44
Update of epidermal growth factor receptor-tyrosine kinase inhibitors in non-small-cell lung cancer
Chen, Y. (2013) · Journal of the Chinese Medical Association · doi:10.1016/j.jcma.2013.01.010 · Cited by 41
Tyrosine Kinase Inhibitors in Lung Cancer
Thomas, A., Rajan, A., & Giaccone, G. (2012) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2012.02.001 · Cited by 45
Induction chemotherapy followed by gefitinib and concurrent thoracic radiotherapy for unresectable locally advanced adenocarcinoma of the lung: a multicenter feasibility study (JCOG 0402)
Niho, S., Ohe, Y., Ishikura, S., Atagi, S., Yokoyama, A., Ichinose, Y., Okamoto, H., Takeda, K., Shibata, T., Tamura, T., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mds012 · Cited by 42
Durvalumab in Stage III Non–Small-Cell Lung Cancer
Copur, M. D., Gauchan, D., & Ramaekers, R. (2018) · New England Journal of Medicine · doi:10.1056/nejmc1716426 · Cited by 43
Role for Surgical Resection in the Multidisciplinary Treatment of Stage IIIB Non–Small Cell Lung Cancer
Bott, M. J., Patel, A. P., Crabtree, T. D., Morgensztern, D., Robinson, C. G., Colditz, G. A., Waqar, S. N., Kreisel, D., Krupnicka, A. S., Patterson, G. A., et al. (2015) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2015.02.033 · Cited by 41
Outcomes of concurrent chemoradiotherapy in patients with stage III non-small-cell lung cancer and significant comorbidity
Phernambucq, E. C. J., Spoelstra, F. O. B., Verbakel, W. F. A. R., Postmus, P. E., Melissant, C. F., van den Brink, K. I. M., Frings, V. G., van de Ven, P. M., Smit, E. F., & Senan, S. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq316 · Cited by 41
Beyond Concurrent Chemoradiation: The Emerging Role of PD-1/PD-L1 Inhibitors in Stage III Lung Cancer
McCall, N. S., Dicker, A. P., & Lü, B. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3269 · Cited by 41
Incidental Receipt of Cardiac Medications and Survival Outcomes Among Patients With Stage III Non–Small-Cell Lung Cancer After Definitive Radiotherapy
Wang, H., Liao, Z. X., Zhuang, Y., Liu, Y., Levy, L. B., Xu, T., Yusuf, S. W., & Gomez, D. R. (2014) · Clinical Lung Cancer · doi:10.1016/j.cllc.2014.09.006 · Cited by 40
Pathways to improving combined modality therapy for stage III nonsmall-cell lung cancer
Schild, S. E., & Vokes, E. E. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv621 · Cited by 40
Combining radiotherapy with targeted therapies in non-small cell lung cancer: focus on anti-EGFR, anti-ALK and anti-angiogenic agents
Wrona, A., Dziadziuszko, R., & Jassem, J. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-552 · Cited by 42
Gefitinib With Concurrent Thoracic Radiotherapy in Unresectable Locally Advanced NSCLC With EGFR Mutation; West Japan Oncology Group 6911L
Akamatsu, H., Murakami, H., Harada, H., Shimizu, J., Hayashi, H., Daga, H., Hasegawa, Y., Kim, Y. H., Kato, T., Tokunaga, S., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.05.019 · Cited by 41
Tumor Cavitation in Patients With Stage III Non–Small-Cell Lung Cancer Undergoing Concurrent Chemoradiotherapy: Incidence and Outcomes
Phernambucq, E. C. J., Hartemink, K. J., Smit, E. F., Paul, M. A., Postmus, P. E., Comans, E. F. I., & Senan, S. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182582912 · Cited by 39
Novel Approaches of Chemoradiotherapy in Unresectable Stage IIIA and Stage IIIB Non-Small Cell Lung Cancer
Stinchcombe, T. E., & Bogart, J. A. (2012) · The Oncologist · doi:10.1634/theoncologist.2012-0020 · Cited by 39
Concurrent Chemotherapy and Radiation Therapy for Inoperable Locally Advanced Non–Small-Cell Lung Cancer
Rosenzweig, K. E., & Gomez, J. E. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.69.9678 · Cited by 39
Treatment Outcomes of Different Prognostic Groups of Patients on Cancer and Leukemia Group B Trial 39801: Induction Chemotherapy Followed by Chemoradiotherapy Compared with Chemoradiotherapy Alone for Unresectable Stage III Non-small Cell Lung Cancer
Stinchcombe, T. E., Hodgson, L. C., Herndon, J. E., Kelley, M. J., Cicchetti, M. G., Ramnath, N., Niell, H. B., Atkins, J. N., Akerley, W., Green, M. R., et al. (2009) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181b27b33 · Cited by 38
Heterogeneity of tumour response to combined radiotherapy and EGFR inhibitors: Differences between antibodies and TK inhibitors
Krause, M., Gurtner, K., Deuse, Y., & Baumann, M. A. (2009) · International Journal of Radiation Biology · doi:10.3109/09553000903232835 · Cited by 38
Time and dose-related changes in radiological lung density after concurrent chemoradiotherapy for lung cancer
Phernambucq, E. C. J., Palma, D. A., Vincent, A. D., Smit, E. F., & Senan, S. (2011) · Lung Cancer · doi:10.1016/j.lungcan.2011.05.010 · Cited by 37
Patient-Derived Xenografts as a Model System for Radiation Research
Willey, C. D., Gilbert, A. N., Anderson, J. C., & Gillespie, G. Y. (2015) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2015.05.008 · Cited by 36
Gefitinib in Non Small Cell Lung Cancer
Costanzo, R., Piccirillo, M. C., Sandomenico, C., Carillio, G., Montanino, A., Daniele, G., Giordano, P., Bryce, J., Feo, G. D., Maïo, M. D., et al. (2011) · BioMed Research International · doi:10.1155/2011/815269 · Cited by 37
Optimizing the Management of Advanced Non-small-Cell Lung Cancer: A Personal View
Vincent, M. D. (2009) · Current Oncology · doi:10.3747/co.v16i4.465 · Cited by 36
EGFR-Mutated Lung Cancer WithT790M-Acquired Resistance in the Brain and Histologic Transformation in the Lung
Scher, K. S., Saldivar, J., Fishbein, M. C., Marchevsky, A. M., & Reckamp, K. L. (2013) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2013.0126 · Cited by 36
Predicting factors of symptomatic radiation pneumonitis induced by durvalumab following concurrent chemoradiotherapy in locally advanced non-small cell lung cancer
Mayahara, H., Uehara, K., Harada, A., Kitatani, K., Yabuuchi, T., Miyazaki, S., Ishihara, T., Kawaguchi, H., Kubota, H., Okada, H., et al. (2022) · Radiation Oncology · doi:10.1186/s13014-021-01979-z · Cited by 36
Safety and efficacy of combined radiotherapy, immunotherapy and targeted agents in elderly patients: A literature review
Belgioia, L., Desideri, I., Errico, A., Franzese, C., Daidone, A., Marino, L., Fiore, M., Borghetti, P., Greto, D., & Fiorentino, A. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.11.009 · Cited by 35
A randomized phase II study comparing induction or consolidation chemotherapy with cisplatin–docetaxel, plus radical concurrent chemoradiotherapy with cisplatin–docetaxel, in patients with unresectable locally advanced non-small-cell lung cancer
Senan, S., Cardenal, F., Vansteenkiste, J., Stigt, J. A., Akyol, F. H., Neve, W. D., Bakker, J., Dupont, J.-M., Scagliotti, G. V., Ricardi, U., et al. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq388 · Cited by 35
How can we optimise concurrent chemoradiotherapy for inoperable stage III non-small cell lung cancer?
Bayman, N., Blackhall, F. H., McCloskey, P., Taylor, P. D., & Finn, C. F. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.11.017 · Cited by 35
Osimertinib (AZD9291) increases radio‑sensitivity in EGFR T790M non‑small cell lung cancer
Wang, N., Wang, L., Meng, X., Wang, J., Zhu, L., Liu, C., Li, S., Li, Z., Yang, Z., Xing, L., et al. (2018) · Oncology Reports · doi:10.3892/or.2018.6803 · Cited by 36
A systematic review and meta-analysis of treatment-related toxicities of curative and palliative radiation therapy in non-small cell lung cancer
Or, M., Liu, B., Lam, J., Vinod, S. K., Xuan, W., Yeghiaian‐Alvandi, R., & Hau, E. K. C. (2021) · Scientific Reports · doi:10.1038/s41598-021-85131-7 · Cited by 35
Adjuvant Therapy in Non–Small Cell Lung Cancer: Future Treatment Prospects and Paradigms
Carbone, D. P., & Felip, E. (2011) · Clinical Lung Cancer · doi:10.1016/j.cllc.2011.06.002 · Cited by 35
Non-small Cell Lung Cancer
Jabbari, S., Hansen, E. K., & Haas-Kogan, D. A. (2010) · Springer eBooks · doi:10.1007/978-0-387-92988-0_15 · Cited by 34
Chemoradiation therapy in nonsmall cell lung cancer
Baas, P., Belderbos, J. S. A., & van den Heuvel, M. M. (2010) · Current Opinion in Oncology · doi:10.1097/cco.0b013e328341eed6 · Cited by 34
Contrasted Outcomes to Gefitinib on Tumoral IGF1R Expression in Head and Neck Cancer Patients Receiving Postoperative Chemoradiation (GORTEC Trial 2004-02)
Thariat, J., Bensadoun, R., Étienne-Grimaldi, M.-C., Grall, D., Penault-Llorca, F. M., Dassonville, O., Bertucci, F., Cayre, A., Raucourt, D. D., Geoffrois, L., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1518 · Cited by 35
The Efficacy and Safety of EGFR Inhibitor Monotherapy in Non-Small Cell Lung Cancer: A Systematic Review
Yang, X., Yang, K., & Kuang, K. (2014) · Current Oncology Reports · doi:10.1007/s11912-014-0390-4 · Cited by 37
Concurrent systemic therapy with radiotherapy for the treatment of poor-risk patients with unresectable stage III non-small-cell lung cancer: a review of the literature
Cardenal, F., Nadal, E., Jové, M., & Finn, C. F. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu229 · Cited by 33
Immunoradiotherapy as an Effective Therapeutic Strategy in Lung Cancer: From Palliative Care to Curative Intent
Chicas-Sett, R., Zafra, J., Morales-Orue, I., Castilla-Martinez, J., Francés, M. Á. B., González-Rodríguez, E., Rodríguez‐Abreu, D., & Couñago, F. (2020) · Cancers · doi:10.3390/cancers12082178 · Cited by 33
Comparison of toxicity and outcomes of concurrent radiotherapy with carboplatin/paclitaxel or cisplatin/etoposide in stage III non–small cell lung cancer
Liew, M. S., Sia, J., Starmans, M. H. W., Tafreshi, A., Harris, S., Feigen, M., White, S. C., Zimet, A. S., Lambin, P., Boutros, P. C., et al. (2013) · Cancer Medicine · doi:10.1002/cam4.142 · Cited by 32
Adjuvant therapy following surgery in non-small cell lung cancer (NSCLC)
Tanaka, F., & Yoneda, K. (2015) · Surgery Today · doi:10.1007/s00595-015-1174-7 · Cited by 31
A Randomized Phase III Trial of Combined Paclitaxel, Carboplatin, and Radiation Therapy Followed by Weekly Paclitaxel or Observation for Patients With Locally Advanced Inoperable Non–Small-Cell Lung Cancer
Carter, D. L., Garfield, D. H., Hathorn, J. W., Mundis, R. J., Boehm, K. A., Ilegbodu, D., Asmar, L., & Reynolds, C. H. (2011) · Clinical Lung Cancer · doi:10.1016/j.cllc.2011.10.005 · Cited by 30
Pulmonary Toxicities of Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer
Hong, D., Zhang, G., Zhang, X., & Liang, X. (2016) · Medicine · doi:10.1097/md.0000000000003008 · Cited by 30
Consolidation systemic treatment after radiochemotherapy for unresectable stage III non-small cell lung cancer
Skrzypski, M. T., & Jassem, J. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.04.001 · Cited by 32
Locally Advanced, Unresectable Non-Small Cell Lung Cancer
Puri, S., Saltos, A. N., Perez, B. A., Le, X., & Gray, J. E. (2020) · Current Oncology Reports · doi:10.1007/s11912-020-0882-3 · Cited by 30
The addition of amifostine to carboplatin and paclitaxel based chemoradiation in locally advanced non-small cell lung cancer: Long-term follow-up of Radiation Therapy Oncology Group (RTOG) randomized trial 9801
Lawrence, Y. R., Paulus, R., Langer, C. J., Werner‐Wasik, M., Buyyounouski, M. K., Komaki, R. U., Machtay, M. X., Smith, C. J., Axelrod, R. S., Wasserman, T. H., et al. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.02.008 · Cited by 29
Long-term survival of locally advanced stage III non-small cell lung cancer patients treated with chemoradiotherapy and perspectives for the treatment with immunotherapy
Vrankar, M., & Stanič, K. (2018) · Radiology and Oncology · doi:10.2478/raon-2018-0009 · Cited by 28
Immunotherapy in non-metastatic non-small cell lung cancer: Can the benefits of stage IV therapy be translated into earlier stages?
Deslypere, G., Gullentops, D., Wauters, E., & Vansteenkiste, J. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835918772810 · Cited by 29
Molecular markers to predict clinical outcome and radiation induced toxicity in lung cancer.
Palmer, J. D., Zaorsky, N. G., Witek, M. E., & Lü, B. (2014) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2072-1439.2013.12.04 · Cited by 28
ACR Appropriateness Criteria® nonsurgical treatment for locally advanced non-small-cell lung cancer: good performance status/definitive intent.
Chang, J. Y., Kestin, L. L., Barriger, R. B., Chetty, I. J., Ginsburg, M. E., Kumar, S., Loo, B. W., Movsas, B., Rimner, A., Rosenzweig, K. E., et al. (2014) · PubMed · Cited by 27
Disease-free survival improved by use of adjuvant EGFR tyrosine kinase inhibitors in resectable non-small cell lung cancer: an updated meta-analysis
Yuan, Y., Huang, Q., Gu, C., & Chen, H. (2017) · Journal of Thoracic Disease · doi:10.21037/jtd.2017.12.58 · Cited by 27
Maintenance therapy in nonsmall‐cell lung cancer
Mok, T. S. K., & Ramalingam, S. S. (2009) · Cancer · doi:10.1002/cncr.24563 · Cited by 27
Adjuvant chemotherapy for resected non-small-cell lung cancer: future perspectives for clinical research
Bonomi, M., Pilotto, S., Milella, M., Massari, F., Cingarlini, S., Brunelli, M., Chilosi, M., Tortora, G., & Bria, E. (2011) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-30-115 · Cited by 27
Concurrent chemoradiotherapy for stage III non-small-cell lung cancer: recent progress and future perspectives (a narrative review)
Łazar-Poniatowska, M., Bandura, A., Dziadziuszko, R., & Jassem, J. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-704 · Cited by 26
Maintenance treatment of advanced non-small-cell lung cancer: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology
Gridelli, C., de Marinis, F., Maïo, M. D., Ardizzoni, A., Belani, C. P., Cappuzzo, F., Ciardiello, F., Fidias, P. M., Paz-Ares, L. G., Perrone, F., et al. (2012) · Lung Cancer · doi:10.1016/j.lungcan.2011.12.011 · Cited by 26
Resectable IIIA-N2 Non-Small-Cell Lung Cancer (NSCLC): In Search for the Proper Treatment
Brascia, D., Iaco, G. D., Schiavone, M., Panza, T., Signore, F., Geronimo, A., Sampietro, D., Montrone, M., Galetta, D., & Marulli, G. (2020) · Cancers · doi:10.3390/cancers12082050 · Cited by 27
Randomized Phase II Study of 3 Months or 2 Years of Adjuvant Afatinib in Patients With Surgically Resected Stage I-III EGFR-Mutant Non–Small-Cell Lung Cancer
Neal, J. W., Costa, D. B., Muzikansky, A., Shrager, J. B., Lanuti, M. D., Huang, J. G., Ramachandran, K. J., Rangachari, D., Huberman, M. S., Piotrowska, Z., et al. (2021) · JCO Precision Oncology · doi:10.1200/po.20.00301 · Cited by 26
Pre-treatment FDG-PET predicts the site of in-field progression following concurrent chemoradiotherapy for stage III non-small cell lung cancer
Ohri, N., Piperdi, B., Garg, M. K., Bodner, W. R., Gucalp, R. A., Perez-Soler, R., Keller, S. M., & Guha, C. (2014) · Lung Cancer · doi:10.1016/j.lungcan.2014.10.016 · Cited by 25
Gefitinib Versus Adjuvant Chemotherapy in Patients With Stage II-IIIA Non–Small-Cell Lung Cancer Harboring Positive EGFR Mutations: A Single-Center Retrospective Study
Xie, H., Wang, H., Xu, L., Li, M., Peng, Y., Cai, X., Feng, Z., Ren, W., & Peng, Z. (2018) · Clinical Lung Cancer · doi:10.1016/j.cllc.2018.05.007 · Cited by 25
Increased CYFRA 21-1, CEA and NSE are Prognostic of Poor Outcome for Locally Advanced Squamous Cell Carcinoma in Lung: A Nomogram and Recursive Partitioning Risk Stratification Analysis
Wang, J., Jiang, W., Zhang, T., Liu, L., Bi, N., Wang, X., Hui, Z., Liang, J., Lv, J., Zhou, Z., et al. (2018) · Translational Oncology · doi:10.1016/j.tranon.2018.05.008 · Cited by 25
Gefitinib for the treatment of non-small-cell lung cancer
Campbell, L., Blackhall, F. H., & Thatcher, N. J. (2010) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2010.481283 · Cited by 25
Durvalumab After Chemoradiotherapy in Patients With Unresectable Stage III Non–Small Cell Lung Cancer
Mooradian, M. J., Cai, L., Wang, A., Qiao, Y., Chander, P., & Whitaker, R. M. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.7542 · Cited by 24
Adjuvant treatment in resected non-small cell lung cancer: Current and future issues
Remón, J., LIANES, P., Torres‐Martínez, S., Velasco, M., Querol, R., & Zanui, M. (2013) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2013.05.017 · Cited by 24
A phase II study of cisplatin with intravenous and oral vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy with oral vinorelbine and cisplatin for locally advanced non-small cell lung cancer
Lerouge, D., Rivière, A., Dansin, É., CHOUAID, C., Dujon, C., Schött, R., Lavolé, A., Pennec, V. L., Fabre, E., Créquit, J., et al. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-231 · Cited by 24
Clinical Outcomes in Non-Small-Cell Lung Cancer in Relation to Expression of Predictive and Prognostic Biomarkers
Singh, N., Bal, A., Aggarwal, A. N., Das, A., & Behera, D. (2010) · Future Oncology · doi:10.2217/fon.10.30 · Cited by 24
Docetaxel in the treatment of non-small cell lung carcinoma: an update and analysis
Wakelee, H. A., & Gubens (2010) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s6499 · Cited by 23
Meta-analysis of cardiovascular toxicity risks in cancer patients on selected targeted agents
Escalante, C. P., Chang, Y.-C., Liao, K.-P. E., Rouleau, T., Halm, J. K., Bossi, P., Bhadriraju, S., Brito-Dellan, N., Sahai, S. K., Yusuf, S. W., et al. (2016) · Supportive Care in Cancer · doi:10.1007/s00520-016-3310-3 · Cited by 24
Radiotherapy and Immunotherapy Combinations for Lung Cancer
Agrawal, V., Benjamin, K. T., & Ko, E. C. (2020) · Current Oncology Reports · doi:10.1007/s11912-020-00993-w · Cited by 23
Adjuvant Treatment of Resected Lung Cancer
Chhatwani, L., Cabebe, E. C., & Wakelee, H. A. (2009) · Proceedings of the American Thoracic Society · doi:10.1513/pats.200807-068lc · Cited by 23
Emerging developments of chemoradiotherapy in stage III NSCLC
Price, A. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.135 · Cited by 23
Single‐arm phase II study of multiagent concurrent chemoradiotherapy and gefitinib in locoregionally advanced squamous cell carcinoma of the head and neck
Rodriguez, C. P., Adelstein, D. J., Rybicki, L. A., Saxton, J. P., Lorenz, R. R., Wood, B. G., Scharpf, J., & Ives, D. I. (2011) · Head & Neck · doi:10.1002/hed.21971 · Cited by 23
Combined Modality Therapy for Stage III Non–Small-Cell Lung Cancer
Anderson, C. S., & Curran, W. J. (2010) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2010.01.007 · Cited by 23
Early Stage Lung Cancer: Progress in the Last 40 Years
Novello, S., Asamura, H., Bazan, J. G., Carbone, D. P., Goldstraw, P. G., Grunenwald, D. H., Ricardi, U., & Vansteenkiste, J. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000327 · Cited by 23
Exploring Radiotherapy Targeting Strategy and Dose: A Pooled Analysis of Cooperative Group Trials of Combined Modality Therapy for Stage III NSCLC
Schild, S. E., Pang, H., Fan, W., Stinchcombe, T. E., Vokes, E. E., Ramalingam, S. S., Bradley, J. D., Kelly, K. L., & Wang, X. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.04.011 · Cited by 23
Self-citation
Maintenance Therapy in Advanced Non-small Cell Lung Cancer
Coate, L. E., & Shepherd, F. A. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181d86e8b · Cited by 22
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Versus Placebo as Maintenance Therapy for Advanced Non-small-cell Lung Cancer: A Meta-analysis of Randomized Controlled Trials
Alimujiang, S., Zhang, T., Han, Z.-G., Yuan, S.-F., Wang, Q., Yu, T., & Li, S. (2013) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2013.14.4.2413 · Cited by 22
Defining the Role of Tyrosine Kinase Inhibitors in Early Stage Non-Small Cell Lung Cancer
Lampaki, S., Lazaridis, G., Zarogoulidis, P., Kioumis, I. P., Papaiwannou, A., Tsirgogianni, K., Karavergou, A., Tsiouda, T., Karavasilis, V., Yarmus, L. B., et al. (2015) · Journal of Cancer · doi:10.7150/jca.11893 · Cited by 22
Radiotherapy and Receptor Tyrosine Kinase Inhibition for Solid Cancers (ROCKIT): A Meta-Analysis of 13 Studies
Tchelebi, L. T., Batchelder, E., Wang, M., Lehrer, E. J., Drabick, J. J., Sharma, N. K., Machtay, M. X., Trifiletti, D. M., & Zaorsky, N. G. (2021) · JNCI Cancer Spectrum · doi:10.1093/jncics/pkab050 · Cited by 22
Treatment-Related Pneumonitis of EGFR Tyrosine Kinase Inhibitors Plus Thoracic Radiation Therapy in Patients With Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis
Meng, Y., Sun, H., Wang, S., Yang, H., & Kong, F. (2023) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2023.09.009 · Cited by 22
A Phase I Study of Temsirolimus and Thoracic Radiation in Non–Small-Cell Lung Cancer
Waqar, S. N., Robinson, C. G., Bradley, J. D., Goodgame, B. W., Rooney, M., Williams, K., Gao, F., & Govindan, R. (2013) · Clinical Lung Cancer · doi:10.1016/j.cllc.2013.11.007 · Cited by 23

Authors: Kelly, K., Chansky, K., Gaspar, L. E., Albain, K. S., Jett, J., Ung, Y. C., Lau, D. H. M., Crowley, J. J., & Gandara, D. R.
Affiliations: Sunnybrook Health Science Centre (CA)
ORCID: Kelly, Karen
Albain, Kathy S.
Ung, Yee C.
Gandara, David R.
Venue: Journal of Clinical Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Published: 2008-05-20
Volume: 26
Issue: 15
Pages: 2450-2456
ISSN: 0732-183X (ISSN-L)
1527-7755
DOI: 10.1200/jco.2007.14.4824
OpenAlex: W2153865661
Cited by: 573
References: 31
Citations by year: 2026: 5 · 2025: 6 · 2024: 11 · 2023: 18 · 2022: 11 · 2021: 31 · 2020: 24 · 2019: 22 · 2018: 39 · 2017: 24 · 2016: 41 · 2015: 40 · 2014: 44 · 2013: 57 · 2012: 41
FWCI: 48.16
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Journal of Clinical Oncology (publishedVersion)
PubMed (publishedVersion)
Funders: AstraZeneca
Sanofi
National Institutes of Health (2u10ca038926-25, 5r01ca037663-18)
National Cancer Institute (CA35192, U10CA004919, CA 35176, CA-11083, CA52654, CA-45377, U10CA035261, CA35281, CA 74811, CA-35261, CA-46282, CA 20319, CA-32102, U10CA074647, CA 45450, CA35119, CA 42777, U10CA045377, CA04919, U10CA058882, U10CA074811, U10CA014028, U10CA045560, U10CA063848, U10CA035178, CA 74647, U10CA045808, CA35128, CA46368, CA46441, CA 63845, U10CA046368, CA45808, CA 45461, CA67575, U10CA035090, CA 14028, U10CA020319, U10CA086780, U10CA011083, CA-58882, CA35178, CA-45807, U10CA013612, CA 37663, U10CA035119, U10CA063850, CA35431, U10CA032102, U10CA046282, U10CA045461, U10CA052654, U10CA045450, U10CA042777, U10CA035281, CA 13612, U10CA063845, U10CA045807, U10CA063844, U10CA035431, CA-35262, U10CA035192, CA 38926, U10CA035262, CA63844, CA86780, U10CA035176, U10CA035128, CA-63850, CA-63848, CA45560, U10CA067575, CA-35090, U10CA046441)
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
Keywords: gefitinib, maintenance therapy, non-small cell lung cancer, stage III NSCLC, inoperable lung cancer, concurrent chemoradiotherapy, cisplatin, etoposide, thoracic radiotherapy, EGFR tyrosine kinase inhibitors, survival, toxic death
MeSH terms: Docetaxel, Gefitinib, Adenocarcinoma, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Cisplatin, Combined Modality Therapy, Etoposide, Female, Follow-Up Studies, Humans, Lung Neoplasms, Male, Middle Aged, Neoplasm Staging, Prognosis, Quinazolines, Remission Induction, Survival Rate, Maximum Tolerated Dose, Taxoids

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks